Proactive Investors - Run By Investors For Investors

Orgenesis showcases publication of diabetes study in Stem Cell Research and Therapy Journal

The developer of advanced cell therapies points out that insulin-dependent diabetes is a disorder that could, in theory, be cured by functional pancreatic islets and the implantation of autologous insulin-producing cells
diabetes logo
Orgenesis is a biotech company focused on cell and gene therapies

Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, on Wednesday announced the publication of a promising diabetes study entitled “The Role of The Vasculature Niche on Insulin Producing Cells Generated by Transdifferentiation of Adult Human Liver Cells” in the February issue of the Journal of Stem Cell Research and Therapy.

Orgenesis points out that insulin-dependent diabetes is a disorder that could, in theory, be cured by functional pancreatic islets and the implantation of autologous insulin-producing cells.

Results of the study, which focused on insulin-dependent diabetes and was carried out in mice, show that the co-implantation of mesenchymal stem cells (MSCs) and endothelial colony forming cells (ECFCs) with autologous insulin-producing cells led to the doubling of survival rates and a three-fold increase in insulin production.

READ: Orgenesis stock climbs after it posts 139% expansion in gross profit for fiscal 2018 on revenue surge

In a statement, Professor Sarah Ferber, chief scientific officer of Orgenesis, praised the study for offering proof that the transdifferentiation process, which is the conversion of one adult tissue or cell into another type of cell, works.

“In this study, we were able to uncover that vasculature is an important factor in generating regenerative properties and is a fitting approach for the treatment of diabetes,” explained Ferber. “Vasculature enacts cell-to-cell communication, inducing a change of the maturation of insulin producing cells and their survival upon implementation.”

Orgenesis is a biotech company focused on cell and gene therapies.

The Germantown, Maryland-based company’s goal is to utilize its know-how and intellectual property to advance new autologous cell therapies to a clinical stage and enable point-of-care cell therapy development and services.

Two of the most common types of stem cell transplants are autologous and allogeneic transplants. Both kinds of stem cell transplantations are a common treatment option for cancers such as leukemia, lymphoma, and multiple myeloma.

An autologous transplant uses a person's own stem cells, while an allogeneic transplant uses stem cells from a donor whose human leukocyte antigens (HLA) are acceptable matches to the patient’s.

Orgenesis shares held steady at $5.20 in morning trade on Wednesday

Contact Ellen at [email protected]

 

View full ORGS profile View Profile

Orgenesis Timeline

Related Articles

Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use